Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Obese or severely obese.~* Initiated an OAC from July 1, 2013 - December 31, 2017; the first DOAC pharmacy claim date during the identification period will be designated as the index date. The first warfarin prescription date will be designated as the index date for patients without any DOAC claim.~* Individuals ≥18 years old as of the index date.~* Had 6 months continuous health plan enrollment with medical benefits (Parts A \& B) for at least 6 months pre-index date (baseline period).~* At least 1 diagnosis of AF prior to or on index date, identified by any medical claim associated with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code of 427.31 or International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code of I480-I482, and I4891.~* Had body weight or BMI value reported within ±6 months of the index date.~Exclusion Criteria:~* Had medical claims indicating a diagnosis or procedure of rheumatic mitral valvular heart disease, heart valve replacement/transplant, venous thromboembolism, or transient AF 6 months prior to or on the index date.~* Had hip/knee replacement surgery within 6 weeks prior to or on the index date.~* Were pregnant during the study period.~* Had an OAC prescription during the 6 months pre-index date.~* Had follow-up time equal to 0 days.~* Had more than one OAC on the index date.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban Group (Type: None): The cohort prescribed apixaban and diagnosed with Atrial Fibrillation
- Warfarin Group (Type: None): patients prescribed warfarin only diagnosed with Atrial Fibrillation.

Based on this trial design, predict the completion outcome and termination type (if applicable).